NCT01449539 · REGISTRY CONDITION SEARCH

Study of Hyperbaric Oxygen Therapy in Addition to Standard Growth Factor Support for Hematopoietic Progenitor/Stem Cell Mobilization

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: NA
Status at capture: TERMINATED
Registry last update: 2015-02-23

The purpose of this study is to evaluate the safety and efficacy of hyperbaric oxygen therapy (HBOT) as a therapeutic option in mobilizing stem cells for autologous stem cell transplant.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Stem Cells Collected

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Patients who are being considered for autologous stem cell transplant as part of their routine care who have failed at least one prior attempt at stem cell mobilization with any of currently available standard regimens using growth factors. * Patients in who the use of Mozobil® is medically justified but is not possible because of insurance or financial reasons * Patients scheduled to begin standard growth factor treatment with Neupogen® as part of routine care. * Patients who have had a bone marrow evaluation performed within one month prior to enrollment as part of routine clinical care or under IRB# 02815. * Patients who have had a chest x-ray or CT Chest within 60 days prior to enrollment. * ECOG performance status ≤ 3 performed within 60 days prior to enrollment which will be determined by history. * Patients who are at least 18 years of age at the time of registration. * Patient must have signed an IRB-approved informed consent and understand the investigational nature of the study. Exclusion Criteria: * Clinically significant hepatic dysfunction as noted by direct bilirubin or AST \>3 times the upper normal limit or clinically significant concurrent hepatitis within 60 days prior to enrollment. * History of New York Heart Association (NYHA) Class III or Class IV heart failure * Recent (\< 6 months) myocardial infarction, unstable angina, difficult to control congestive heart failure, uncontrolled hypertension, or difficult to control cardiac arrhythmias from medical history. * Untreated pneumothorax from medical history. * Uncontrolled seizure disorder from medical history * Uncontrolled insulin dependent diabetes (verified by routine labs in medical record) * History of severe claustrophobia * Severe COPD (FEV1 \< 50% of predicted on pulmonary function test) performed within 60 days prior to enrollment * Untreated ear barotraumas from medical history * Pregnancy or currently breastfeeding (females of childbearing potential must agree to use adequate contraception during the study). A urine pregnancy test will be performed prior to initiating HBOT. * Patients currently receiving Bleomycin, Cisplatin, Disulfiram, Doxorubicin, and Sulfamylon. * Any other condition that the PI determines may jeopardize the safety of the subject during the course of the study
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

interventions

description
Treatment Monday through Friday in a monoplace hyoerbaric chamber 100% oxygen at 2.0 atmospheres (14.7 PSI or the equivalent of being under 33 feet of sea water) for 90 minutes at pressure. Treatment lasts 2 hours as time is allowed for gradual pressurization and depressurization. Each subject will be treated for two weeks for a total of 10 HBOT treatments
name
Hyperbaric Oxygen Therapy
other Names
HBOT
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 8
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Total stem cells collected from all participants at one week post-study treatment
measure
Number of Stem Cells Collected
time Frame
one week post-treatment

Full study description

brief Summary: The purpose of this study is to evaluate the safety and efficacy of hyperbaric oxygen therapy (HBOT) as a therapeutic option in mobilizing stem cells for autologous stem cell transplant.
detailed Description: Subjects will receive HBOT daily for 10 days in conjunction with standard growth factor treatment regimens for stem cell mobilization. The role of HBOT in stem cell mobilization as well as its role on oxidative stress will be evaluated.

Source references